Financials

News Ideas Technicals Forecast

ULTIO fundamentals

Overview Statements Statistics Dividends Earnings Revenue

Key facts

—

—

—

—

—

—

—

—

About

Ultimovacs AS operates as a pharmaceutical company. The firm engages in the development of novel immunotherapies against cancer. Its product, UV1, is a therapeutic cancer vaccine that activates the immune system to recognize telomerase. The company was founded on January 26, 2011 and is headquartered in Oslo, Norway.

Valuation

Fundamental metrics to determine fair value of the stock

Summary

No data available

There's currently no market capitalization, revenue or net income data to show.

Valuation ratios

Growth and Profitability

Company’s recent performance and margins

Dividends

Dividend yield, history and sustainability

ULTIO does not pay dividends

The company has not previously paid dividends and at the moment there is no information about whether it is going to pay them in the future

Financial health

Financial position and solvency of the company